Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Thrombocytosis 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Meningeal Carcinomatosis 1Melanoma 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Hepatitis B, Chronic 1Hepatitis B 1Fallopian Tube Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma 1Brain Neoplasms 1

Interventions

Azacitidine 26venetoclax 20Cyclophosphamide 17fludarabine phosphate 14Whole-Body Irradiation 13Biopsy 13fludarabine 12Specimen Handling 12Tacrolimus 11Mycophenolic Acid 11Decitabine 10Stem Cell Transplantation 9Peripheral Blood Stem Cell Transplantation 9Injections 8Cytarabine 8Busulfan 8decitabine and cedazuridine drug combination 7Melphalan 7X-Rays 5Hematopoietic Stem Cell Transplantation 5Cyclosporine 5Sirolimus 4ruxolitinib 3olutasidenib 3enasidenib 3cedazuridine 3Magnetic Resonance Spectroscopy 3Idarubicin 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Chronic × peginterferon alfa-2b × 1 year × Clear all
NCT07468916 2026-05-06

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

Jonsson Comprehensive Cancer Center

Phase 2 Not yet recruiting
35 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Thrombocytosis, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡